Germany's medical cannabis programme has undergone a remarkable transformation. Since legislative changes in 2024 made it easier for patients to access treatment through public health insurance, patient numbers have surged and the range of conditions being treated has expanded significantly.
How Germany did it
The key reform was removing the requirement for special authorisation before doctors could prescribe cannabis-based medicines. This simple regulatory change had a dramatic effect: prescribing rates increased, more doctors became willing to prescribe, and patient access improved substantially.
What the UK can learn
The German experience demonstrates that regulatory simplification can be more effective than wholesale legislative reform. For the UK, the lesson is clear: removing bureaucratic barriers and providing clear guidelines for clinicians could unlock access without requiring new primary legislation.
Challenges remain
Germany's system isn't perfect. Reimbursement rates, supply chain issues, and variations in prescribing practice remain challenges. But the direction of travel is positive — and the UK would do well to study it closely.
